Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

• DOI: 10.1073/pnas.1710877114
• Publication Date: 2017-11-20T19:50:19Z
• Authors: Nan Guo Ring; Dietmar Herndler-...; Kipp Weiskopf; Liang Shan; Jens-Peter Volkmer; Benson M. George; Melanie Lietzenmayer; Kelly M. McKenna; Tejaswitha J. Naik; Aaron McCarty; Yunjiang Zheng; Aaron M. Ring; Richard A. Flavell; Irving L. Weissman
• Keywords: CD47; Cancer Immunotherapy

Significance Cancer immunotherapy is a promising therapeutic intervention. However, complete and durable responses are only seen in fraction of patients who have cancer. Although cells the myeloid lineage frequently infiltrate tumors limit success, currently approved immunotherapies primarily target tumor-infiltrating T natural killer lymphocytes. The inhibitory receptor signal regulatory protein-α (SIRPα) represents myeloid-specific immune checkpoint that engages “don’t eat me” CD47. Here, we developed an anti-human SIRPα antibody, KWAR23, which combination with tumor-opsonizing antibodies, greatly augmented neutrophil macrophage antitumor activity vitro vivo. Thus, KWAR23 may represent candidate for therapies achieve greater number